Results 11 to 20 of about 125,001 (364)

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.

JAMA cardiology, 2022
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS).
Hirotoshi Watanabe, T. Morimoto, M. Natsuaki, Ko Yamamoto, Y. Obayashi, M. Ogita, S. Suwa, T. Isawa, T. Domei, K. Yamaji, Shojiro Tatsushima, Hiroki Watanabe, M. Ohya, H. Tokuyama, T. Tada, H. Sakamoto, Hiroyoshi Mori, Hiroshi Suzuki, Tenjin Nishikura, K. Wakabayashi, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, Y. Morino, K. Kadota, Y. Furukawa, Y. Nakagawa, T. Kimura   +31 more
semanticscholar   +1 more source

Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30‐day results

Catheterization and Cardiovascular Interventions, Volume 100, Issue 7, Page 1291-1299, December 1, 2022., 2022
Abstract Background Severe tricuspid regurgitation (TR) is independently associated with increased morbidity and mortality. Percutaneous transcatheter approaches may offer an alternative for patients not amenable to surgery. Methods TriCLASP is a prospective, single‐arm, multicenter European post‐market clinical follow‐up study (NCT04614402) to ...
Stephan Baldus, Niklas Schofer, Jörg Hausleiter, Kai Friedrichs, P. Lurz, Philipp Luedike, Christian Frerker, G. Nickenig, Edith Lubos, Roman Pfister, M. I. Körber, Daniel Kalbacher, Michael Näbauer, C. Besler, Amir Abbas Mahabadi, Marcel Weber, M. Zdanyte, C. B. Ren, Tobias Geisler   +18 more
wiley   +1 more source

Ticlopidine and Clopidogrel [PDF]

Circulation, 1999
Abstract —The thienopyridines ticlopidine and clopidogrel are inhibitors of platelet function in vivo. Their mode of action has not been defined, but it appears that they require conversion to as yet unidentified metabolites that are noncompetitive antagonists of the platelet ADP receptor. Inhibition
Martin J. Quinn, Desmond J. Fitzgerald
openaire   +2 more sources

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source

Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube

Journal of Pharmaceutical Health Care and Sciences, 2021
Background In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube.
Manahito Aoki, Midori Naya, Shiho Arima, Kaori Shinohara, Masahiro Kato, Kiyoshi Shibuya, Masaki Ohtawa, Tohru Nagamitsu, Katsuya Otori   +8 more
doaj   +1 more source

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Frontiers in Pharmacology, 2021
Objective: To explore the treatment effect of statins used together with clopidogrel on cerebral infarction (CI).Methods: One hundred and thirty non-clopidogrel resistant patients were divided into a dynamic clopidogrel resistant (DCR) group and a ...
Hong Ting Shi, Yong Yuan Chen, Xiao Ying Li, Jian Hua Luo, Guang Hong Zhong, Jia Jia Hu, Min Zhang, Bo Rong Zhou   +7 more
doaj   +1 more source

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

Circulation, 2022
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy ...
Jeehoon Kang, Kyung-Woo Park, H. Lee, D. Hwang, Han-Mo Yang, S. Rha, J. Bae, N. Lee, S. Hur, J. Han, E. Shin, B. Koo, Hyo‐Soo Kim   +12 more
semanticscholar   +1 more source

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)

Clinical Cardiology, Volume 45, Issue 12, Page 1303-1310, December 2022., 2022
Abstract Background Chronic kidney disease (CKD) is a known risk factor of atherosclerotic cardiovascular disease (ASCVD). Per the 2018 American Heart Association/American College of Cardiology cholesterol guidelines, high‐risk ASCVD patients with CKD and low‐density lipoprotein cholesterol (LDL‐C) levels ≥ $\ge $ 70 mg/dL should take a high‐intensity ...
Aleesha Shaik, Mikhail Kosiborod, James A. de Lemos, Qi Gao, Katherine E. Mues, Shushama Alam, Deepak L. Bhatt, Christopher P. Cannon, Christie M. Ballantyne, Robert S. Rosenson, The GOULD Investigators   +10 more
wiley   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

Clinical Cardiology, Volume 45, Issue 12, Page 1143-1146, December 2022., 2022
Abstract Background The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo‐controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER).
Marc P. Bonaca, Michael Szarek, E. Sebastian Debus, Mark R. Nehler, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs   +9 more
wiley   +1 more source